However, the co-addition of apoA-I:CIGB-258 ameliorated the CML-induced wound damage and improved the wound healing up to 35%, 37%, 53%, and 56% by 1:0, 1:0.1, 1:0.5, and 1:1 molar ratio, suggesting a dose-dependent manner of CIGB-258 to enhance the wound-healing activity. This evidence concerns the gene APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive.